Protocol Ledger

NCT07210723 · Phase II/III · RECRUITING

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Interventional Phase II/III clinical trial protocol NCT07210723 sponsored by Kardigan in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-13 Enrollment: 332 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07210723
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)332 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07210723
Protocol FieldVerified Registry Value
NCT IdentifierNCT07210723
Consolidated Lead SponsorKardigan
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment332 participants (ESTIMATED)
Registered Start Date2026-02-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI